Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary

February 27, 2025

NASDAQ US Health Care Biotechnology earnings 84 min

Earnings Call Speaker Segments

Diane Weiser

executive
#1

Good afternoon, and thank you for being with us today. Robert Blum, who serves as President and Chief Executive Officer, will kick things off with a look at the quarter and what's happened recently; Andrew Callos, EVP and Chief Commercial Officer, will discuss activities around commercial readiness for aficamten; Fady Malik, EVP of R&D, will share updates on the clinical development program for aficamten; Isaac Ciechanover, EVP Corporate Development and Chief Business Officer, will give an update on the business development deal we announced recently, framed within our corporate development efforts; Stuart Kupfer, SVP and Chief Medical Officer, will cover omecamtiv mecarbil, CK-586, and our earlier stage development pipeline; Sung Lee, EVP and Chief Financial Officer, will walk through a financial overview of the quarter just ended and talk about our 2025 financial guidance; and last, Robert will go over the key milestones we expect in the year ahead. Please be aware that parts of what we discuss, including answers to your questions, include statements about future events and performance instead of historical facts, and these are forward-looking statements. What actually happens could differ materially from what these forward-looking statements project. Details about factors that could make our actual results differ materially from those in these forward-looking statements can be found in our SEC filings, including our current report on our fourth quarter 2024 financial results furnished to the SEC today on Form 8-K. We have no obligation to update any forward-looking statements after this call. And with that, I'll hand the call over to Robert.

Robert Blum

executive
#2

Thanks, Diane, and I appreciate everyone being on the call today. The fourth quarter of 2024 proved to be an extremely fruitful period, capping off a strong year. Above all, we achieved significant progress toward possible regulatory clearances and the commercial introductions of aficamten that would follow in a number of geographies. FDA has accepted our NDA. EMA has validated our MAA, and the NMPA in China has accepted our NDA with priority review. With regulatory filings now on file across the U.S., Europe, and China, we are conducting simultaneous regulatory engagements that could bring aficamten to patients globally. Given our PDUFA date of September 26, 2025, our commercial preparation efforts in the United States are at their height, and at the same time we are building the groundwork for our launch activities in Europe. Over the near term, we anticipate continuing the activities already underway with FDA to support their NDA review; we have been answering questions and getting ready for clinical site and other inspections, and we recently filed our 120-day safety update with FDA. We expect to take part in a mid-cycle meeting with FDA in March. Before that meeting, I want to set expectations that we do not intend to provide detailed updates after it, since FDA's NDA review will still be in progress; even so, we continue to expect a differentiated label and < > profile for aficamten should FDA approve it. In both SEQUOIA-HCM and FOREST-HCM, among patients with oHCM, we saw a favorable overall safety profile, LVEF stability, rapid dose titration, and an absence of treatment interruptions tied to episodes of heart failure or heart failure hospitalizations related to LVEF, nor did we see any clinically meaningful drug-drug interactions. We believe these characteristics all align with the intrinsic properties of aficamten. Turning to the regulatory review of aficamten in Europe, after our MAA was validated in late December, we expect to keep engaging with EMA throughout their review by answering requests for information and preparing for inspections. Our next key milestone in these regulatory interactions with EMA is receipt of the day 120 list of questions, expected in April. As you know, we intend to commercialize aficamten ourselves in the U.S. and Western Europe. In other key geographies during the fourth quarter, Sanofi, with our participation, acquired from CORXEL the rights to develop and commercialize aficamten in China. Also, in November, we announced our new collaboration with Bayer involving a license agreement for aficamten in Japan. These are two strong pharmaceutical company partners in the two leading markets outside the U.S. Both Europe and Cytokinetics share a dedication to cardiology, and each side contributes significant know-how, means, and scope that should help us get aficamten to more HCM patients who need it and push us toward our aim of bringing our medicines to patients around the world. At the same time, we're moving forward our later stage development effort for aficamten, with several potential label expansion clinical trials currently underway. Looking at the near term, we anticipate reporting top line results from MAPLE-HCM during Q2, and should this trial yield positive data, it could once more represent a label expansion opportunity for aficamten after a possible FDA approval. In the meantime, we keep growing our specialty cardiology franchise and pushing innovative pipeline advances, which ensures we are not just a one product company. During Q4, we launched COMET-HF, a confirmatory Phase three clinical trial of omecamtiv in patients who have heart failure with severely reduced ejection fraction. More recently, we launched AMBER- HFpEF, a Phase 2 clinical trial of CK-586 in patients who have heart failure with preserved ejection fraction. The wins we achieved across the last quarter show our clear vision, strategic execution, and responsible investment in our muscle biology platform. This year, we're nearing a defining moment, with key milestones ahead that will shape our future; as multiple programs move forward in our specialty cardiology franchise, along with progress in our early-stage neuromuscular pipeline and ongoing innovation in our research labs, we're positioned to drive meaningful progress that positively impacts patients' lives and creates enduring value for shareholders who back our mission; with that, I'll now hand the call to Andrew.

Andrew Callos

executive
#3

Appreciate that, Robert. We've got substantial momentum behind our launch readiness for aficamten as we head through 2024, and we're now in the last phase before a possible U.S. approval and the September launch of our first medicine. For a successful launch, here's what we're guiding toward as priorities: expanding awareness of the category and clearly conveying what sets aficamten apart, energizing and activating prescriptions from new cardiologists, locking in access plus a copay that's affordable for HCM patients, and delivering outstanding patient support. Notably, we're glad to observe ongoing category growth in the count of patients on a cardiac myosin inhibitor, or CMI. That continued market expansion and wide awareness benefits Cytokinetics, since it signals a rising opportunity for aficamten in a market that remains largely untapped. Cytokinetics will concentrate on boosting market awareness, deepening category penetration, and widening cardiology adoption of CMIs with aficamten. With that aim, during Q4 we're proud to push greater education and awareness around HCM through the debut of HCM Beyond The Heart, an unbranded disease awareness effort that features actual HCM patients. Back in October, we introduced this campaign aimed at HCPs, encouraging them to search more deeply for HCM and to practice whole person care. Early engagement numbers from the website and emails sit above the industry benchmark for our target audience. Come January, we broadened HCM Beyond the Heart to include patients, adding a website along with educational tools and resources centered not merely on the condition but on how it affects a patient's life beyond their heart; that marks one more exciting milestone as we progress toward the PDUFA date later in the year. In the meantime, we keep building and honing our branded HCP promotional campaign for aficamten, which right now is undergoing testing with HCPs. To back our aim of securing product and market access following approval, we've maintained our dialogue with payers while pushing ahead on standing up a strong patient support program. That covers contracting with strategic partners, deciding the scale and design of our customer facing Nurse Navigator team, and building a bespoke patient experience offering. We likewise moved forward on operational planning for our sales force, such as completing the sales training curriculum, sales territory configurations, and deployment, and we wrapped up our sales representative recruiting process, which kicks off in late Q1. Past the U.S. launch, we're additionally ramping up commercial launch related work on international infrastructure to back a possible European approval for aficamten. Late last year, we brought on key leadership roles in Europe, among them leaders for marketing, finance, and human resources, plus in country leadership in France and the U.K., after having hired a leader in Germany earlier in the prior year. Recent planning work sits ahead of a possible European approval, covering validation of our reimbursement strategy and the initial preparation of dossiers for HTA submission throughout the U.K. and Western E.U. markets. I feel good about how far we've come in getting ready for the commercial rollouts of aficamten in both the U.S. and Europe, and about where we stand right now on our roadmap for commercial readiness. So with that, I'll hand things over to Fady.

Fady Malik

executive
#4

Thank you, Andrew. As Robert said, we recently filed the 120-day safety update with FDA, and it includes ten additional months of safety data from FOREST-HCM. Those longer-term findings line up with what we showed previously from FOREST-HCM, and with the safety profile for aficamten that appears in the NDA submission, and we believe there is no sign of a higher risk of EF excursions or heart failure events. While FDA goes through the NDA, we keep responding to their questions and getting ready for clinical site and other inspections. Robert also noted that we anticipate taking part in a mid-cycle meeting with FDA during March. Turning to what we did in the fourth quarter to broaden the evidence base for aficamten. At the American Heart Association Scientific Sessions in November, we shared data from two prespecified analyses of SEQUOIA-HCM along with one analysis of FOREST-HCM. That extends our efforts to make data from this program accessible to the medical community. Among those presentations were analyses of post exercise oxygen uptake recovery, patient quality of life and guideline eligibility for septal reduction therapy, and aficamten had a favorable impact on all of them. Beyond sharing data that quarter, our managed healthcare MSL team kept up preapproval information exchange, actively involving national and regional payers in scientific discussions about oHCM and aficamten, and let payers know our PDUFA date. Scientific engagement with HCM specialists carried on as well, with discussions centered on the SEQUOIA-HCM results, including the primary results and secondary data analyses. Now moving to the ongoing clinical trials program for aficamten: after finishing enrollment in MAPLE-HCM during the third quarter of last year, we are still running the trial, gathering data and moving toward database lock. We remain on track to report top line results in the second quarter of this year, and we expect a presentation of the full results at a later medical meeting to follow. Should MAPLE-HCM prove positive, it would give us a chance to position aficamten as a potential monotherapy for treating oHCM after approval. In the meantime, we have kept running ACACIA-HCM, the pivotal Phase three clinical trial in non-obstructive HCM, CEDAR-HCM in a pediatric population of patients with symptomatic oHCM, and naturally FOREST-HCM, the ongoing open label extension clinical study. FOREST-HCM keeps expanding, with more than 400 patients now enrolled, close to 300 patients having at least one year of follow-up and more than 90 having two years of follow-up. We are glad to say that patient enrollment in ACACIA-HCM has moved quickly in recent months, thanks to our highly engaged sites. We have finished site activations across North and South America, Europe and Israel and are happy with the baseline characteristic of the population. Findings from this trial mark a key future milestone for the potential label expansion trajectory for aficamten into non-obstructive HCM. Although it accounts for roughly 1/3 of the HCM population today, nHCM seems to be growing faster than oHCM when it comes to diagnoses, so we expect it will ultimately make up nearly half of HCM diagnoses. Therefore, this represents a significant portion of people who require attention, especially given that nHCM has no effective medical or surgical treatment options, which is different from oHCM. From the standpoint of clinical development as a whole, our efforts during the fourth quarter concluded what was genuinely an extraordinary year, marked by many data presentations and publications in journals with high impact. As we get closer to possible approval and the launch of aficamten in oHCM during this year, we are eager to continue building upon and publishing that expanding clinical evidence supporting aficamten. At this point, I will hand things over to Isaac.

Isaac Ciechanover

executive
#5

Appreciate that, Fady. Like Robert mentioned, we wrapped up two new partnerships in Q4, and together those deals will support both the development and commercialization of aficamten in major regions around the world. We were very happy to enter into a collaboration and licensing agreement with Bayer for developing and commercializing aficamten in Japan. When you look at how attractive the economics are for a cardiovascular drug, this deal really is in a class of its own. Cytokinetics gets EUR50 million in upfront payments, plus the chance to earn another EUR90 million linked to milestones all the way through commercial launch, along with EUR490 million in commercial milestone payments from Bayer once certain sales milestones are hit, and tiered royalties on aficamten net sales in Japan. Bayer is going to run a Phase 3 study in Japanese oHCM patients to back up a possible marketing approval for aficamten in Japan, adding to SEQUOIA-HCM and FOREST-HCM, and Cytokinetics intends to bring ACACIA-HCM and CEDAR-HCM into Japan as well. This is the kind of arrangement in Japan we've been working toward for quite a while, as you're aware. Cytokinetics and Bayer share the same strong dedication to cardiology, and by the end of that process Bayer emerged as the best-suited partner, one with the right capabilities to deliver aficamten to Japanese patients. Also, in Q4, Sanofi picked up exclusive development and commercialization rights for aficamten from CORXEL, the company previously known as Ji Xing, in China. Under the terms of this deal, Cytokinetics can still get as much as $150 million from Sanofi in milestone payments tied to development and commercialization, plus royalties on aficamten sales in China that land somewhere between the low and high teens. On top of that, Cytokinetics is set to collect further payments linked to how the agreement between Sanofi and CORXEL gets carried out. Our work with CORXEL has been extremely fruitful over the years, and we're glad to now be joining forces with Sanofi, drawing on their cardiology know-how to deliver aficamten to patients across China. These two agreements, taken together, help broaden how far aficamten can reach in important markets around the world. At this point, with partners established in both China and Japan, plus our commercial operations growing in the U.S. and Europe, we're now focusing on ways to extend our geographic footprint further for aficamten. We're also looking at how to spark outside R&D efforts and chase fresh business goals that would strengthen what's already in our pipeline, alongside discoveries coming from our internal labs. With that in mind, we aim to add more new chemical entities into clinical development by drawing on external innovation, looking for therapies that could complement our late-stage cardiovascular portfolio and our newer neuromuscular pipeline. Our Vision 2030 makes clear that we're pursuing growth into additional modalities, and we plan to do that by developing things in-house while also finding outside partners — companies in the industry as well as academic groups. Over the next twelve months, expect to see more happening on the business and corporate development side here at Cytokinetics, both in terms of getting aficamten to patients around the world and in terms of ways we might strengthen our R&D pipeline that reflect movement toward the vision we've laid out. I'm looking forward to sharing updates as these efforts progress; with that, I'll hand it over to Stuart.

Stuart Kupfer

executive
#6

Thanks, Isaac. I'm glad to share the latest on our specialty cardiology franchise's later-stage development programs, along with the earlier-stage neuromuscular clinical research we're conducting. First, omecamtiv mecarbil, which is a cardiac myosin activator. This quarter, we launched COMET-HF, a confirmatory Phase 3 clinical trail involving patients who have symptomatic heart failure with severely reduced ejection fraction below 30%. Since the trial got underway, our investigators have shown tremendous enthusiasm — they understand how substantial the unmet need is among this high-risk population and are keen to get patients enrolled. Right now, the trial is enrolling across the United States, and regulatory submissions are complete in Canada, the U.K. and the rest of Europe. Investigators who've previously worked with omecamtiv mecarbil keep contacting us to ask about joining COMET-HF, and our steering committee is now fully seated, bringing together the foremost heart failure leaders from the countries where the trial will run. Now I'll turn to CK-586, our next cardiac myosin inhibitor. In January of this year, we kicked off AMBER-HFpEF, a Phase 2 placebo controlled double-blind trial assessing safety, tolerability, pharmacokinetics and the pharmacodynamic profile of CK-586 among patients with symptomatic heart failure with preserved ejection fraction and LVEF greater than or equal to sixty percent. AMBER-HFpEF should enroll roughly 60 patients across three 12-week dose escalation cohorts, with doses spanning 160 mg to 600 mg once daily. CK-586's potential treatment benefits include greater cardiac relaxation, which would lead to better diastolic function, easing of heart failure symptoms and improved exercise capacity, and through this trial we expect to build a body of evidence supporting those outcomes. Our aim is to finish enrollment of the first two cohorts in the second half of the year. Last, beyond our specialty cardiology franchise, in the fourth quarter we were happy to launch a Phase one study of CK-089, a fast skeletal muscle troponin activator. That study includes both single and multiple ascending dose cohorts. CK-089 came out of our pioneering research in neuromuscular disease and was optimized through what we learned previously. CK-089 is built to amplify skeletal muscle response to nerve input, extending time to fatigue and boosting muscle force and power, with possible therapeutic use in a specific type of muscular dystrophy. We expect this Phase 1 study to wrap up within 2025 and look forward to updating you on our progress in this key area of clinical research, since it highlights a second vertical for our company. With that, I'll hand things over to Sung.

Sung Lee

executive
#7

Thanks, Stuart. We're happy to share the financial results for our fourth quarter and for the full year 2024. Let's begin with the balance sheet: as of the close of Q4 2024, we held roughly $1.2 billion in cash, cash equivalents and investments, which compares with $1.3 billion when the third quarter of 2024 ended. During Q4 2024, cash, cash equivalents and investments fell by about $60 million, and we did get a boost from receiving a $52.4 million, or €50 million, payment from Bayer tied to the exclusive license for developing and commercializing aficamten in Japan. Now on to the income statement: revenue for Q4 2024 came in at $16.9 million, versus $1.7 million in the comparable period of 2023. For the whole of 2024, revenues reached $18.5 million, up against $7.5 million in 2023. Both the fourth quarter of 2024 and the full year 2024 total revenues got a lift from a $15 million upfront payment from CORXEL related to assigning CORXEL's rights for developing and commercializing aficamten in Greater China to Sanofi. R&D expenses in the fourth quarter totaled $93.6 million, compared with $85 million during the same period in 2023. For the full year 2024, R&D expenses amounted to $339.4 million, versus $330.1 million in 2023. The year-over-year rise in both the fourth quarter and the full year came mainly from pushing our clinical trials forward and from higher personnel-related costs, including stock-based compensation. G&A expenses for Q4 2024 were $62.3 million, compared with $44.1 million in the same period of 2023. G&A expenses for the full year 2024 were $215.3 million, compared with $173.6 million in 2023. The year-over-year increase in both periods was driven mainly by investments toward commercial readiness and by higher personnel-related costs, including stock-based compensation. Net loss in the fourth quarter of 2024 was $150 million, or $1.26 per share, versus a net loss of $136.9 million, or $1.38 per share, in the same period of 2023. For the full year 2024, net loss was $589.5 million, or $5.26 per share, versus a net loss of $526.2 million, or $5.45 per share, in 2023. Now turning to our 2025 financial guidance: we expect GAAP operating expense, made up of R&D and SG&A expenses, to land between $670 million and $710 million. Stock-based compensation within that GAAP operating expense is anticipated to fall between $110 million and $120 million. If you strip stock-based compensation out of GAAP operating expense, you get a range of $550 million to $600 million. Our capital allocation priorities are unchanged, and our resources will concentrate on the following. First, preparing for a possible U.S. commercial launch of aficamten in September of this year, which includes bringing on as many as 150 sales reps in the U.S. during the third quarter of 2025. Next, we're pushing our pipeline forward through key chances to broaden the label for aficamten, along with clinical studies of omecamtiv mecarbil and CK-586, and third, through funding for our muscle biology platform. The operating expense growth we expect compared with last year will mostly come from money put toward getting ready commercially for aficamten's possible launch in patients who have obstructive HCM. Thanks to our solid balance sheet and the ability to raise additional capital, we're in a good spot to carry out our strategy, and we think that can deliver sustainable growth powered by the specialty cardiology franchise. With that said, I'll turn things back over to Robert.

Robert Blum

executive
#8

Thanks, Sung. What we accomplished in Q4 of 2024 has positioned us for a decisive year ahead. As we get closer to a possible approval in the U.S. and the commercial introduction of aficamten during 2025, we're deliberately bringing our longer-range vision into alignment while also refining where we concentrate operationally on the milestones and advances that sit nearest to us. With the proper infrastructure, capabilities, partners and team now in place, we have confidence in our capacity to execute and to secure a number of wins across our expanding footprint. Earlier in the year, we introduced Vision 2030 — our set of five-year strategic goals crafted to drive Cytokinetics toward becoming the foremost muscle-focused specialty biopharmaceutical company, one committed to substantially bettering patients' lives via global access to novel medicines. Vision 2030 functions as an aspirational roadmap built from five objectives: innovation, ignition, impact, inspiration and ingenuity. Those objectives spell out the way we intend to secure product approvals, bring about wider access to our medicines, foster more equitable access and push forward our pioneering research for the benefit of patients, shareholders and employees. In keeping with that vision for what lies ahead, we recently shared that Robert Landry has been appointed to our Board of Directors. Bob carries more than 30 years of financial and operational know-how in pharma, having most recently spent 11 years as Regeneron's Chief Financial Officer, a period in which he helped steer that company as it scaled and brought medicines to market around the world. We're glad to have him on our Board at this particular moment in our corporate development. As we look toward 2025, our attention will remain on FDA approval and U.S. commercial launch readiness for aficamten, along with carrying out our continuing clinical trials programs. During the past year, we brought in more than $1 billion when combining existing cash with access to new capital, which gives us the runway to carry out the U.S. launch of aficamten while also moving our R&D pipeline forward and making investments in a fiscally prudent, capital efficient manner to build lasting value for shareholders. I feel optimistic about what lies ahead for us in 2025. So let me now walk through our upcoming milestones. For aficamten, we anticipate moving NDA review activities forward with FDA to back the potential U.S. approval of aficamten in the second half of this year. We anticipate pushing go-to-market strategies forward and getting ready to commercially launch aficamten in the U.S. in the second half of this year, subject to approval by the FDA. We anticipate carrying on go-to-market plans in Germany and broadening commercial readiness activities in Europe during 2025 as we prepare for potential approval by the EMA in the first half of 2026. We anticipate coordinating with Sanofi to support the potential approval of aficamten in China in the second half of 2025, pending approval by the NMPA. And we anticipate reporting top line results from MAPLE-HCM in Q2 of this year. We also anticipate finishing enrollment of ACACIA-HCM in the second half of this year, and finishing enrollment of the adolescent cohort in CEDAR-HCM, likewise in the second half of 2025. Regarding omecamtiv mecarbil, our plan is to keep enrolling patients in COMET-HF all the way through 2025, which would let us finish enrollment in 2026. As for CK-586, the goal is to wrap up enrollment for the initial 2 patient cohorts in AMBER-HFpEF during this year's second half. Turning to CK-089, we anticipate finishing the Phase 1 study within this year. Then, on the subject of our preclinical development and research that's ongoing, we look to carry on those existing preclinical development and research efforts aimed at further programs centered on muscle biology. Operator, at this point we're ready to take questions on the call, please.

Paul Choi

analyst
#9

Greetings, all. And good afternoon to you as well. Kahlil here, joining on Paul’s behalf. I suppose what we’d like to ask concerns MAPLE-HCM. Should the findings come back favorable, what’s the right way to view the expected schedule for a possible label expansion, presuming an approval in September? Also, in the meantime, how might those favorable findings align with the company’s marketing approach? Many thanks.

Robert Blum

executive
#10

First I’ll ask Fady to address the initial portion, and then Andrew for the latter portion, please.

Fady Malik

executive
#11

Yes, hello. Regarding when we might broaden the label, we'd definitely want to review the data and then make a call on that timing. My expectation is that it lands in 2026 rather than 2025, since our PDUFA date currently sits at September 26, 2025. Still, I believe everything hinges on timing and whatever else may be happening then.

Andrew Callos

executive
#12

When it comes to how we're taking this to market, that second trial actually gives us confirmatory data backing up the primary study — on both the safety side and the efficacy side — and that's reassuring for doctors who keep seeing many of the same primary and secondary endpoints. It unlocks a group of cardiologists who treat exclusively with beta blockers. Of the roughly 2,000 cardiologists out of 500, or with the vast majority of CMI prescribers today — and according to our market research — this would bring in more prescribers, many of whom believe beta blockers might be sufficient. It also provides that extra evidence and could even shape guidelines and shift treatment toward first line eventually, though that definitely takes much longer.

Robert Blum

executive
#13

Perhaps we should find out what Andrew has to say. Apologies—just a quick point directed at Andrew. It's my view that if MAPLE-HCM turns out positive, it might help drive additional category expansion, since a greater number of cardiologists could feel more at ease prescribing a cardiac myosin inhibitor. Beyond that, we'd expect it to bring about further category penetration for aficamten within that broader market. Still, I'd characterize that as more incremental than transformative relative to what we anticipate the label opportunity from SEQUOIA-HCM will be.

Paul Choi

analyst
#14

Great. Thank you.

Robert Blum

executive
#15

Thank you.

Cory Kasimov

analyst
#16

Hi there, good afternoon, and thanks for fitting in my question. To build on what Andrew said earlier regarding growing the market, I believe it's fairly widely accepted that HCM is a condition that goes heavily under diagnosed. So I'm wondering what you expect will happen on that front now that 2 companies are out there in the market spreading awareness and highlighting the advantages of cardiac myosin inhibitors. Given that something like 70% to even 80% percent of patients still have no diagnosis, is there a reasonable benchmark for where that figure might land, let's say, 3 to 5 years down the road? Thank you.

Robert Blum

executive
#17

Thank you. I'll hand it over to Andrew, please.

Andrew Callos

executive
#18

Absolutely. That's a really good question. I think, as you're aware, whenever guidelines are revised, whenever studies come out, whenever we and other companies are at congresses where doctors go to pick up on new data, those things definitely boost how far treatments reach into the market and boost diagnosis through awareness and education. What I think we've observed across the past several years is that obstructive HCM keeps pushing diagnosis rates higher in line with the population, but the non-obstructive form is expanding at a rate in the double digits. So I think as time goes on, non-obstructive could even be 50 to 50, or a bit bigger than obstructive when it comes to the total patient population. Our current estimate is that roughly 30% of the population gets diagnosed; and with these rates and sort of the direction they're heading, that very well might land in the fifty percent range over the next, let's say, three to five years.

Robert Blum

executive
#19

When it comes to comparable companies, we're also taking a look at the broader landscape. And I genuinely think that both the amyloidosis area and the pulmonary arterial hypertension area provide comps regarding what a next in class drug might mean for greater diagnosis as well as category penetration. We view those as solid proxies.

Cory Kasimov

analyst
#20

Okay, that sounds fine. I appreciate it. Thanks, everyone.

Robert Blum

executive
#21

You're welcome.

Robert Blum

executive
#22

Hi, Salim.

Salim Syed

analyst
#23

Hey, Robert. I appreciate you taking the question. There's one thing people keep asking about — and I'm sure the same is true on your end — and I'd really like to hear your perspective, which is the 28-day dataset coming from Edgewise. We're basically trying to understand how it fits into your framework, and whether there's anything specific you're watching for. And on that same note, do you see even the slightest chance that, if they move forward, they could emerge from this with no REMS whatsoever? Thanks — at least going by the preclinical data. Thank you.

Robert Blum

executive
#24

Yeah, that's clearly a very slippery slope, and we won't go down it by talking about another company's ongoing development program; even so, I do appreciate the question; that being said, it's early days, and I'll hand it to Fady so he can address this, just as others have asked him to, though my suggestion would be that we allow the data and evidence to speak for itself. Fady?

Fady Malik

executive
#25

Yeah. Hey, Salim. As Robert mentioned, we're still at an early stage of this program, I'd say. To get a real handle on how safe this drug is when it's given to thousands of people, you're going to require data from hundreds of patients. And before you have that understanding, it's too soon to say anything — even if I did want to weigh in on what their safety profile and monitoring might eventually look like. So I'll just stop there.

Robert Blum

executive
#26

We can't wait to see what the data show. Clearly, those results will reveal whether there's a chance to bring a new mechanism treatment into oHCM that could be potentially differentiated. We feel great about the data we have backing aficamten, both on the efficacy side and for safety, ease of use, and other things that were built into aficamten in line with intrinsic properties. And as we anticipate potential approval and a potential commercial launch, we have a lot of confidence that we're in a very positive position. That said, we'll examine these data whenever they come out later — in the first quarter, I guess, based on what we gather.

Salim Syed

analyst
#27

Okay, perfect.

Robert Blum

executive
#28

Thank you so much. Thank you.

Jim Condulis

analyst
#29

Thanks for the opportunity to ask, and congratulations on the progress. One brief item from me, regarding REMS. I realize you can only say so much, but I'm curious how you're thinking about whether mavacamten's REMS will be relaxed in the U.S. If that did occur, how would it change your view of the possible scenarios for aficamten's REMS? In that case, would you still describe a differentiated REMS as differentiated in the maintenance setting as well? Or would that depend more on other components of the REMS? I'm interested to hear whatever you're able to share on that front. Thanks.

Robert Blum

executive
#30

Sure. As before, I want to avoid saying anything that draws comparisons. With that caveat, the BMS earnings call caught our attention, particularly what they said regarding shifts tied to the EMA label. We're eager to find out, presumably during Q2, how the FDA might react to a filing seeking to loosen some of the limits that currently apply under the existing REMS for mavacamten, Camzyos. Our market research has been extensive, and we still see points of differentiation that matter quite a bit for aficamten, aligning with its intrinsic properties. Echo frequency is among them, though there are a number of others as well. Perhaps I'll turn things over to Andrew to discuss what our market research has shown, along with what we anticipate regarding a distinct risk mitigation profile, should approval come through.

Andrew Callos

executive
#31

Appreciate that, Robert. When it comes to differentiation, perhaps the best place to begin is with the data itself. Our label — the guidance we follow for claims related to differentiation — ought to be shaped by that data. We're currently looking into quite a few dimensions of differentiation, and from a market research standpoint, those efforts are progressing nicely. So this particular aspect might be one of them, or it might move ahead alongside others, but additional ones exist as well. Should this end up being loosened across the entire category, I'd say that genuinely benefits the category. At present, the overwhelming majority of patients receive no CMI treatment. If monitoring less often during the maintenance phase brings more patients into the fold with the CMI, and encourages more physicians to prescribe the CMI, well, that's the sort of thing where a rising tide lifts everyone. So we're eager to hear the FDA's position. My understanding is the date falls in April, and we will of course proceed on differentiation, since our label is shaped by the data.

Robert Blum

executive
#32

Our objective, which we have repeated on numerous occasions, is to make certain that a greater number of cardiologists prescribe cardiac myosin inhibitors to a larger patient population. Based on what we continue to estimate, more than 80% of those who qualify could potentially gain from treatment with a cardiac myosin inhibitor, and as prevalence rises, that figure grows. We hold a strong conviction that aficamten, should it receive approval, will offer a differentiated profile, in terms of both its label and risk mitigation. So we will have to see how things unfold, but hopefully that addresses what you asked.

Jim Condulis

analyst
#33

Yes, I appreciate that context. Thank you.

Tess Romero

analyst
#34

Hi, Robert and everyone. Thanks for fielding our questions this evening, and I'm looking forward to ACC. So, drawing on what you've heard from physicians and KOLs, do you believe it's recognized that aficamten doesn't carry the same pharmacogenomic and DDI burden as Camzyos, given how each drug is metabolized in relation to a patient's CYP2C19 genotype versus yours? If that's not the case, what approach would you take to educate doctors on this point? And on a related note, just to be clear, will the pharmacy need to do any monitoring regarding concomitant meds with aficamten? Thanks so much.

Robert Blum

executive
#35

Good questions. Perhaps I'll ask Fady and Stuart to weigh in, and then Andrew if he'd like to add anything.

Fady Malik

executive
#36

Jess, I believe what you're asking about will ultimately come down to the label we secured for aficamten. That said, the physicians we've engaged with—including those who ran our clinical studies—see a distinction: aficamten's drug interaction profile, for instance, does not touch 2C19, and it involves only a small number of clinically meaningful interactions. They've certainly been taught that and behave accordingly. Watching concomitant medications is standard practice, always. No drug anywhere is completely immune to interactions of any kind—even aficamten isn't—but whatever interactions we do see would be fairly infrequent and unusual, and doctors would receive education about those too. Still, I question whether a formal monitoring program or anything of that sort is truly required. We've never implemented one in our trials, and we've encountered no problems so far.

Robert Blum

executive
#37

Just to clear that up, your question was about pharmacy. Stuart or Andrew, would either of you like to weigh in on that? Pharmacy.

Andrew Callos

executive
#38

So basically, in the scenario we consider most likely, we don't anticipate that any REMS program would include pharmacy monitoring — the kind where a pharmacist has to reach out to a patient and discuss medications already being taken along with possible interactions between drugs. That's just not something we see happening.

Tess Romero

analyst
#39

Thanks, everyone.

Leonid Timashev

analyst
#40

Afternoon, everybody. Yeah, I appreciate you giving me the chance to speak. My question concerns the endpoints for ACACIA, plus perhaps a few points of comparison with the rival HCM trial. I'm not trying to be a back-seat driver weighing in on another company's research, but could you discuss what might differ between KCCQ-23 and KCCQ-12? Also, why did you land on one primary endpoint built around KCCQ instead of adding pVO2 as a primary too — was that choice driven by your internal review of your own data, or by discussions with the FDA? Any insight would be welcome. Thanks so much.

Robert Blum

executive
#41

Certainly. I'll turn it over to Fady, and to Stuart as well if he has anything to add.

Fady Malik

executive
#42

Okay, so regarding KCCQ — my view is that it's a patient reported outcome. We looked at how aficamten affected KCCQ during our Phase 2 trial in nHCM. Even though that was an open label experience, there was a meaningful impact on KCCQ. That being said, I believe regulators typically want to see a drug's effect on things beyond just KCCQ. They want to see gains in exercise and in NYHA class — a consistency, so to speak, across functional and symptomatic endpoints. And ACACIA as currently designed has both. It includes an exercise endpoint as a secondary endpoint and KCCQ as a primary endpoint. As you pointed out, ODYSSEY has a dual primary endpoint with both Peak VO2 and KCCQ in parallel, assessed as part of a primary. I think practically speaking, there's not that much of a difference between the two approaches. Both are designed to assess the strength of the evidence with respect to patient reported outcome and other functional metrics. And I think regulators clearly want to see a consistency across both of those domains. Hopefully that answers your question, Leo.

Leonid Timashev

analyst
#43

That's great. Thank you.

Akash Tewari

analyst
#44

Hi. Zaki here, sitting in for Akash. Appreciate you taking our question. Regarding non-obstructive HCM, it appears that both Bristol's ODYSSEY study and your ACACIA trial are aiming to titrate patients toward greater exposure levels. Looking at cohort 4 of Redwood, the final proBNP values appear comparable to what was seen with the lower dose in MAVERICK. The real issue, though, is whether putting patients on 20 mg in ACACIA can demonstrate greater efficacy. Given the SEQUOIA results available thus far, how feasible do you believe it is to maintain patients at that 20 mg dose across the entire thirty six weeks without EF problems? Also, do you have any view on whether a slower titration, similar to what ODYSSEY is showing, could be preferable for the nHCM population?

Robert Blum

executive
#45

there are several pieces to that, so I'll hand it over to Fady and Stuart.

Fady Malik

executive
#46

Alright, I suppose I'll go ahead and take that one. To put it plainly and briefly, in REDWOOD we gave patients doses ranging from 5 mg to 15 mg; 85% of them reached 15 mg and got there within six weeks of starting treatment, and a lot of those people could still go up to 20 mg. Honestly, I don't believe there's any real distinction in heart function between someone with nHCM and someone with oHCM. As a result, you'd anticipate a comparable distribution of doses across both groups, possibly tilted somewhat toward the higher end in NHM, since you aren't halting titration because of hitting gradient-related targets. In REDWOOD, what we observed was a dose-dependent drop in NT-proBNP, with larger reductions coming from the higher doses. That's why I'd say the approach we chose for ACACIA rests squarely on what REDWOOD taught us, correct? It's one-to-one; the way we dose is nearly identical, and the pace of dosing is nearly identical too. And when you're building a Phase 3 trial on top of a Phase 2 trial, all of that helps. So I'd say we feel quite sure about how dosing was handled in that study.

Akash Tewari

analyst
#47

Thanks so much, everyone.

David Lebowitz

analyst
#48

Hello there. Ike Lee <<inaudible>> here, filling in for David Lebowitz. I appreciate you taking my question. What we'd like to know is whether you could give us some guidance on what to expect, especially regarding the primary endpoint of exercise capacity as we approach the MAPLE-HCM readout. Should we anticipate a comparable magnitude of benefit in this head-to-head comparison against beta blockers to what was seen in SEQUOIA — around 5% to 8%, perhaps 10% improvement in exercise capacity from baseline? Also, given that the endpoint is the same, does the degree of clinical meaningfulness shift at all for this trial compared with the ones conducted previously? Thank you.

Robert Blum

executive
#49

Those are good questions. The way we'll likely address them is by discussing how the study was designed and what it was powered to show, and I'll turn it over to Fady for his thoughts

Fady Malik

executive
#50

Sure, happy to take that one. So MAPLE was set up as a study intended to evaluate how aficamten and metoprolol affect exercise capacity, and its statistical power is built around detecting roughly a 2.0 gap separating those two agents. Given that in SEQUOIA we came in at 1.75, I'd say that's a fairly sensible expectation to hold — and 1.75 carried very, very strong statistical significance. When you shift to the matter of clinical meaningfulness, any figure exceeding 1 is regarded as clinically meaningful, and the 1.74 we saw in SEQUOIA is certainly something we view in that light. Evidence exists indicating that mortality and morbidity may be linked to Peak VO2, and that shifts in Peak VO2 of that size carry meaningful consequences for long-term morbidity and mortality. So I'd say any such change of 5% to 8%, or 10%, would amount to a clinically meaningful gap separating the two. And once more, as I mentioned before, this won't purely come down to the size of the Peak VO2 difference — it will also hinge on how consistent the treatment effect looks across endpoints. It will hinge on safety. It will hinge on tolerability. In my view, all of those factors deserve weight when assessing how aficamten performs as monotherapy versus metoprolol as monotherapy. Thanks for the question.

Sean McCutcheon

analyst
#51

Hello, everyone. Thanks for taking my question this afternoon. Perhaps I can expand on what was asked just before. When it comes to MAPLE, the patients you're bringing in have a percent predicted Peak VO2 below 100%, while for SEQUOIA, apart from a single patient, you're mostly bringing in people under 80% predicted. In terms of obstruction causing exercise capacity deficits, how are we supposed to view this patient population, and how does that compare with SEQUOIA, if there's any difference at all? Thanks.

Stuart Kupfer

executive
#52

Hello, I'm Stuart Kupfer. What we saw in SEQUOIA, I believe, was that a threshold of under 90% or under 80 made no meaningful difference when it came to these patients' incapacity. Given how much obstruction was present and the fact that these patients had substantial symptoms, it seemed clear they already had a considerable deficit in their ability to exercise. So we simply came to understand that we could loosen that criterion while still bringing in patients with a fairly significant deficit, and we think that for aficamten, these patients might see benefit from being treated with aficamten.

Srikripa Devarakonda

analyst
#53

Hello, this is Alex speaking instead of Srikripa. We appreciate it. The momentum we're seeing in 2025 has us encouraged. There's one business-related item I'd like to raise. Regarding mavacamten, we've picked up that cardiologists and their practice sites might face constraints because they lack enough monitoring devices to titrate the high patient volumes they handle, which has led to referrals toward more specialized facilities. From your perspective, we're curious whether you've come across this too. Could aficamten in the future potentially be given by a wider spectrum of HCPs? Also, has your market research identified any constraints tied to equipment availability in target markets both outside and within the U.S.?

Robert Blum

executive
#54

Yes; we did see that note from your equity research analyst about this, and about how echo infrastructure in certain places might have been holding back uptake beyond centers of excellence. Perhaps I'll turn it over to Andrew to share what he's gathered from market research on this topic and whether that might or might not carry over to what's being learned in Europe.

Andrew Callos

executive
#55

We examined echo capacity throughout the U.S. — in specialized centers, academic centers, urban centers, and community settings too. Right now it isn't a burden, nor is it something that's sort of cutting capacity or stopping patients from possibly receiving treatment. So I'd say there are other difficulties when it comes to initiating treatment outside, perhaps, academic centers and centers of excellence, but by and large that isn't tied to echo capacity. When we turned to Europe, Europe is a market more concentrated than the U.S.; typically in Europe you must begin in a hospital, in a community center. It isn't as varied regarding how many physician's offices you need to visit — usually you're actually going to a center. And since Europe generally has, by country, a single payer system, and they make it part of the reimbursement process for a specialty medication, it's fairly standard for prescribing to be restricted to one of these institutions, and these institutions have capacity as well.

Robert Blum

executive
#56

At times it's hard to tell what's cause and what's effect, or which is the cart and which is the horse. Our belief is that most Camzyos usage right now sits with a small group of prescribers who are located at centers of excellence. Greater experience brings with it the ability to work through a REMS program. So does that let you conclude there's a smaller problem beyond centers of excellence? Our view is that familiarity with cardiac myosin inhibitors generally goes hand in hand with wider and greater uptake of the cardiac myosin inhibitor that's already on the market. Should aficamten win approval, we hope to add to more education, more awareness, more growth and expansion of the category past centers of excellence, which might be a rising tide lifting the class; and that could, we hope, deliver benefit to aficamten as we expect it to become a category leader regardless of whatever concerns might exist around echo capacity. I hope that's helpful.

Srikripa Devarakonda

analyst
#57

Yes, that's completely logical, and thank you; every one of us is focused on the coming year.

Robert Blum

executive
#58

Thanks.

Robert Blum

executive
#59

Good afternoon.

Roanoke Ruiz

analyst
#60

Hello there, and good afternoon to all of you. My question is somewhat different from the others. I was wondering whether you might expand a little further on what you hope to accomplish down the road — I believe you brought up BD as well as corporate development over the next several years. It sounds as though you would be open to adding to your R&D pipeline. I'm curious if you can share any details regarding the stage of an asset, mechanisms, indications, and so forth that would interest you, whether sourced internally or externally. Also, how would you weigh that against your present expectations for cash runway?

Robert Blum

executive
#61

Sure. I'll have Isaac offer his thoughts first, then Sung, and after that I might add a few remarks of my own.

Isaac Ciechanover

executive
#62

Absolutely, and I appreciate you asking that. For us, the key priority is staying dedicated to what we know best in muscle biology while surveying the entire landscape — what others are developing outside our walls and what we're building ourselves — so that we can assist in pushing forward whichever programs are furthest along. On the licensing side, we've been engaged, and continue to engage, in active conversations with academic groups and research institutes that have preclinical work underway, plus we're evaluating early stage clinical development efforts where our own know-how could move those programs ahead. Naturally, we approach this with financial discipline in mind and with an eye toward where our impact could be largest. Small molecules have been our central area, and as we mentioned earlier during our remarks, having the ability to explore additional modalities matters a great deal to us, since we observe that shift occurring across the field, and we intend to remain at the leading edge.

Sung Lee

executive
#63

Yeah. And when it comes to cash runway at Roanoke, our view is that we've got several years of it as we enter this year, and that's backed by the $1.2 billion we're starting with. Beyond that, as you're aware, we can tap additional capital through Royalty Pharma, up to $500 million. On top of that, we stand to gain from certain near-term milestones tied to the BD deals we signed in the prior year involving aficamten outside the U.S.; so our position here is quite strong. For this year specifically, we anticipate cash utilization landing in the low $500 million. So you can sort of do the arithmetic yourself — given everything I've laid out regarding where capital comes from, we figure we currently have multiple years of runway.

Robert Blum

executive
#64

To expand on that a bit — let me be clear that aficamten and our later-stage pipeline stay at the center, since that's where our investment capital gets put to best use. What Isaac brought up is meant more deliberately to supplement, complement, and create adjacency with what we're pursuing in the earlier stages of our research, and the capital commitments tied to that will be modest compared with the overall spend. So it's really about building training wheels for Cytokinetics as we aim to deliver on our Vision 2030, alongside what we're doing organically, in order to add some inorganic complement — particularly where it could sit adjacent to work already underway, where we can mitigate risk and, with new modalities, enable a transition toward some non-small molecule approaches. Don't take that to mean we're heading into more expensive modalities such as gene therapies and cell therapies — that isn't our intention.

Roanoke Ruiz

analyst
#65

Understood. Thanks.

Robert Blum

executive
#66

Thank you.

Robert Blum

executive
#67

Hi, Joe.

Joe Pantginis

analyst
#68

Hey, everyone. Thanks for taking my question. Good afternoon. So I don't know whether you're able to talk about this at this point, since everything is in motion. But as we get closer to your mid-cycle meeting with the FDA, is there anything you can share about the main questions that remain open or any possible rate limiting steps? And then, on omecamtiv, is there anything you might be able to tell us about COMET-HF and how enrollment is trending, perhaps in relation to GALACTIC, given that there are extra screening criteria? Thanks.

Robert Blum

executive
#69

Sure; so you answered your own question regarding the ongoing FDA interactions; we really can't say anything beyond the fact that we feel very good about where we stand given the ongoing activities. And as we get close to a mid-cycle meeting, we believe we're well positioned to handle any questions we might receive from FDA. When it comes to comment and enrollment sites compared with GALACTIC, perhaps I could ask Fady or Stuart to weigh in on that.

Stuart Kupfer

executive
#70

Appreciate that, Joe. So, as you're aware, enrollment for COMET-HF got underway in the latter part of last year. And we're in a position to take advantage of everything we've learned from GALACTIC when it comes to which investigators are best suited to take part in the trial; plus we benefit from an excellent data set we can pull from that supports, I believe, the hypothesis that omecamtiv mecarbil is going to prove even more effective among these patients at higher risk; and with that, enrollment is moving along at the pace we projected. We'll keep going throughout the year; our plan is to wrap up enrollment next year; and so the studies are on track as planned.

Robert Blum

executive
#71

Regarding what you asked, we're taking plenty of lessons from GALACTIC, and since we ran GALACTIC, we think that puts us in a stronger position to understand where COMET should head, which should let that study enroll quickly. We'll share more on this as the year goes on.

Joe Pantginis

analyst
#72

Thanks again.

Robert Blum

executive
#73

Thank you.

Robert Blum

executive
#74

Good afternoon.

Mayank Mamtani

analyst
#75

Good afternoon, everyone. We appreciate you fielding our questions, and congratulations on the advancement. Perhaps I could pivot to the CK-586 HFpEF trial. As I recall, you stated that the initial pair of cohorts — the low dose and the mid dose — are being enrolled, with those finishing before this year ends. Would you be able to discuss how the higher dose cohort depends on those first two groups being completed, and perhaps also what information you hope to gain regarding tolerability as well as, clearly, the biomarkers in that HFpEF study? Thank you for answering our question.

Robert Blum

executive
#76

I'll perhaps turn that over to Stuart, if you don't mind.

Stuart Kupfer

executive
#77

Appreciate it. The trial was deliberately built to allow for flexibility. As you pointed out, we're aiming to finish the first 2 cohorts before the year is out, and using what we learn from those 2 groups, we'd then decide whether it makes sense to move ahead with cohort number 3, or possibly try another dose instead. So the design does allow for adjustment, and in my view that's a real strength of this study. When it comes to the trial's endpoints, the top priority is looking at safety and tolerability within this HFpEF population. We're going to gather biomarker information, cardiac biomarkers, anti proBNP, plus we'll be assessing pharmacokinetics and looking at how ejection fraction is affected. Those are among the main endpoints we'll be examining, since this is primarily a dose finding kind of study. Thanks. Is there anything else — hopefully that addresses what you were asking?

Mayank Mamtani

analyst
#78

Indeed, that answers it. Thanks. I appreciate that.

Robert Blum

executive
#79

Thanks.

Robert Blum

executive
#80

Hi there, Yasmeen.

Yasmeen Rahimi

analyst
#81

Hey, Robert. Thanks a lot for sharing all those wonderful updates. So one thing we've been curious about — the odyssey study's baseline demographics came out not long ago. I'd really like to hear what Fady thinks about that study, and what caught your attention. Just a few remarks. I appreciate the remarks made during this call that favorable results from ODYSSEY and from MAPLE keep driving more adoption of CMIs in this sizable market. We're talking about a million patients here, which is a significant figure, a highly addressable group. So if you could just offer some thoughts on that. I realize ACACIA is right now completely in enrollment mode, but perhaps are there any particular differences that catch your eye when you examine that baseline population — that would be useful. And I'll get back in line.

Fady Malik

executive
#82

Yes. Hello. Well, I'd say the baseline characteristics weren't surprising, and these are individuals who have notable symptoms, they have elevated biomarkers, reduced exercise capacity, every one of those things that we anticipate finding in a population that is an HCM population. What I find surprising, though, is how closely they resemble the oHCM patients, apart from a gradient in the biomarker and other deficits that they have; so I think that points to the reality that there are many highly impacted patients with nHCM. We've watched both their trial enroll very well; we've watched our trial enroll very well; this is a condition that's likely not as uncommon as people first believed. And I think the effectiveness of CMIs in them should — will be clarified by the results; but there's similarity in many respects to the oHCM patients, I think that bodes well for what we might expect to see.

Yasmeen Rahimi

analyst
#83

Thank you, Fady.

Robert Blum

executive
#84

Hello, Charles.

Charles Duncan

analyst
#85

Hi there, good afternoon. Robert, and to the whole team, congratulations on a fantastic 12 months of advancement. A lot of strong questions have already come through, so I'll contribute one regarding business development. I'm simply curious whether you might describe what type of work Sanofi carried out with respect to the China market. Clearly, it appears as though that could be rather sizable. I'm wondering if you could share any detail on, let's call it, the unmet need in that region and how you foresee the pace at which it gets developed. Also, would you expect milestones still within this year when it comes to cash payments, or perhaps even early in the next one? Thanks.

Robert Blum

executive
#86

Yes. We have been extremely impressed with how much Sanofi has jumped in, ramped up, and elevated its efforts in significant ways. I'll have Isaac address that, and then Sung can speak to the latter portion of your question.

Isaac Ciechanover

executive
#87

Yeah, so like Robert mentioned, Sanofi and the way they handled things really stood out to us. Just to be clear, CORXEL and Sanofi were the two sides in this deal. From what we gather, though, more than one party had shown interest. Everyone recognizes there's an unmet need in China that hasn't been addressed. China doesn't have any REMS programs in place. So from that angle, I think it fit nicely into what Sanofi brings to the table — their ability to capture all the upside that aficamten offers. That's why they came into the collaboration. Since that point, I can share that we've been in very active conversations with them regarding a possible approval this year. As you're aware, there are milestones tied to approval, but those hinge on that event occurring within this calendar year. If it doesn't, they'll roll over into 2026.

Sung Lee

executive
#88

Absolutely. And Charles, to build a bit further on what was asked regarding milestones, we are anticipating significant milestones during this year. What I'd add is that, naturally, since we have several partners involved, I won't speak to any one partner specifically, but what I can say is that these milestones relate to clinical as well as regulatory achievements. To give you a sense of it, we might qualify for as much as $35 million altogether across the partners we work with.

Robert Blum

executive
#89

Also, like I said, they have made some notable improvements when it comes to schedules, projections, production, and supply needs. Perhaps I could have Andrew weigh in regarding how big the market is in China. Andrew, is your microphone muted?

Andrew Callos

executive
#90

Correct, Charles. When we look at population, China is likewise a market that's concentrated. Roughly 400,000 patients have a diagnosis, and just above 1,000 hospitals account for the overwhelming majority — over 80% — of those patients. Probably many more patients exist in rural and community settings who remain undiagnosed, so that number could definitely rise as time goes on. The KOL universe is fairly small as well, coming in at under 500. That's essentially the launch point for the China market in terms of where growth will begin. So there's certainly a high unmet need. And once more, similar to a rare disease, this is definitely a concentrated market with plenty of available patients in China.

Robert Blum

executive
#91

My view is that the potential in China may be getting less credit than it deserves, and we'd urge equity research analysts to conduct their own analysis of that market, though Sanofi's approach to seizing this chance has really stood out to us. Operator?

Robert Blum

executive
#92

Greetings, Jason.

Jason Butler

analyst
#93

Hey there, Robert. I appreciate you taking my question. You brought up that the safety update we sent to FDA included extra data coming from FOREST-HCM. Could you speak to what portion of those data — whether measured in patients or in patient years — comes from the period once the protocol amendment took effect that reduced how often echoes are monitored? Also, if you're able, please comment on whether the safety profile looks consistent both before and after that protocol amendment was put in place? And finally, is there any further protocol amendment being contemplated for FOREST-HCM when it comes to echo monitoring? Thank you.

Robert Blum

executive
#94

These are good questions. Let me hand it over to Fady, please.

Fady Malik

executive
#95

Yes. Hello, Jason. The protocol amendment, I believe, was implemented in the prior year, though I'd note that not much information has built up so far from patients who've undergone monitoring echoes every six months. Even so, let me point out that we have, quite literally, thousands of six-month — roughly three-month monitoring echoes, and you observe minimal effect from those on either dose adjustments or patient safety; therefore, as time passes, likely during this year, additional six-month monitoring will build up among those patients. Right now, we have no additional protocol amendments planned for forest. And I don't believe — what I think I highlighted in my remarks was that it appears, as additional data comes in, aficamten's profile doesn't appear to shift, and the safety we've seen and shared before stays fairly strong. We will be refreshing those data with these new data cuts shortly.

Robert Blum

executive
#96

Those figures are going to be shared with everyone. To add to Fadi's point, the encouraging part is this: regardless of whether ECHO was done at 3-month intervals or at 6-month intervals, our confidence in aficamten, in how safe and tolerable it is, remains strong, and the data we keep seeing is encouraging and, in our view, backs up what we expect in terms of differentiated risk mitigation. Thanks, Jason.

Robert Blum

executive
#97

Hey, Jason.

Jason Zemansky

analyst
#98

Hi there. Good afternoon. Nice work on the progress. And thanks for fitting us in. I was hoping to get a bit more detail on what you said about moving into the first line setting. Could you talk about your approach there, perhaps not going fully into the community-based setting, but at least stepping outside the centers of excellence, where these patients show up much more often. What are some of the obstacles in getting prescribers on board who might be less at ease giving a CMI? How much does it hinge on the REMS itself, and what uptake do you realistically expect?

Robert Blum

executive
#99

Sure. So once again that's a question with several parts. We'll do our best to address it. I'll turn it over to Andrew, with the caveat that when it comes to specific strategy, we likely won't go into detail, but instead speak in general terms. Andrew?

Andrew Callos

executive
#100

Yeah. So regarding the first part of what you asked about first line setting, that's not something we're worried about in the near term. Typically what happens is that guidelines get revised. Payers definitely and doctors definitely prefer trying beta blockers initially. They're simple to prescribe. They're fairly low cost with broad access. But as time goes on, you certainly could see first line treatment, and this will definitely supply the evidence. Some patients are unable to take beta blockers, some have contraindications, some cannot tolerate them, and this supplies the evidence that a CMI such as aficamten is definitely, if those studies are positive, effective. Our market research indicates that a subset of doctors—especially those working in community settings—may not be well educated about what a therapy such as a CMI could offer, and some simply don't care much, particularly when the burden of monitoring is taken into account. For a portion of these physicians, that very issue becomes a reason to accept that a disease modifying therapy is a convincing basis for belief, which helps get them on board. Another point: if you look at cardiovascular launches, or launches in general, the trajectory tends to be linear across a two-to-four-year period. We reviewed the most recent 8 to 10 cardiovascular launches, and after that you see a steep growth curve. To be emphatic, the reason is that you're bringing aboard a larger number of prescribers, and not only the KOLs — meaning the specialized centers and academic centers in this instance. Then, after you're able to move past roughly 500 or 600 physicians, who represent the great bulk of the CMI market as it stands now — approximately 80% — and reach the thousands of cardiologists who today are familiar with this disease and treat it, that is genuinely the point at which the market will take off. These patients, along with maintenance, will begin moving out into the community, where a physician will maintain them, and they'll be going to congresses. So this is simply the usual sort of growth and adoption pattern, perhaps slowed somewhat by the monitoring requirement, but maple for the reasons I gave should certainly be of help. Hopefully that answers your question.

Jason Zemansky

analyst
#101

Yes. Appreciate the color. Thanks.

Robert Blum

executive
#102

Thank you.

Robert Blum

executive
#103

Thanks, operator, and thanks to everyone who joined today's call. We appreciate your ongoing backing and your interest in Cytokinetics. In our view, 2024 proved to be a really robust year for Cytokinetics and positions us well for 2025 — a year in which we aim to fulfill what our science promises, along with more than 25 years devoted to this field of biology, now for possible patient benefit. We think we're carrying out our strategy quite effectively, and we've laid out for you the important milestones for the year ahead. We're eager to keep you updated on how things go; and with that, operator, we're ready to wrap up the call now.

Operator

operator
#104

Thank you. This concludes today's conference call. <<operator_signoff>>.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.